Resources Management Corp CT ADV lessened its position in Puma Biotechnology Inc (NASDAQ:PBYI) by 27.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,615 shares of the biopharmaceutical company’s stock after selling 600 shares during the quarter. Resources Management Corp CT ADV’s holdings in Puma Biotechnology were worth $32,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently added to or reduced their stakes in the business. NumerixS Investment Technologies Inc lifted its position in Puma Biotechnology by 969.5% in the 4th quarter. NumerixS Investment Technologies Inc now owns 2,139 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 1,939 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new stake in Puma Biotechnology in the 4th quarter worth approximately $61,000. Rothschild & Co. Asset Management US Inc. lifted its position in Puma Biotechnology by 12.4% in the 3rd quarter. Rothschild & Co. Asset Management US Inc. now owns 35,267 shares of the biopharmaceutical company’s stock worth $1,617,000 after buying an additional 3,895 shares in the last quarter. Legal & General Group Plc lifted its position in Puma Biotechnology by 46.8% in the 4th quarter. Legal & General Group Plc now owns 14,657 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 4,676 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new stake in Puma Biotechnology in the 3rd quarter worth approximately $251,000. Institutional investors own 91.92% of the company’s stock.
NASDAQ:PBYI traded up $0.03 during midday trading on Friday, reaching $32.89. The stock had a trading volume of 787,235 shares, compared to its average volume of 710,740. Puma Biotechnology Inc has a 1-year low of $17.60 and a 1-year high of $68.90. The company has a current ratio of 3.02, a quick ratio of 2.99 and a debt-to-equity ratio of 4.43. The firm has a market capitalization of $1.27 billion, a PE ratio of -11.00 and a beta of 0.70.
A number of research firms have recently weighed in on PBYI. BidaskClub downgraded shares of Puma Biotechnology from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 16th. JPMorgan Chase & Co. restated a “sell” rating on shares of Puma Biotechnology in a report on Monday, April 1st. Cowen restated a “hold” rating and set a $68.00 price target on shares of Puma Biotechnology in a report on Friday, March 1st. Zacks Investment Research downgraded shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Finally, Citigroup raised their price target on shares of Puma Biotechnology from $67.00 to $70.00 and gave the company a “buy” rating in a report on Friday, March 1st. Six research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. Puma Biotechnology has an average rating of “Hold” and an average price target of $51.91.
In related news, insider Alan H. Auerbach sold 8,825 shares of the firm’s stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $24.74, for a total value of $218,330.50. Following the transaction, the insider now directly owns 4,165,812 shares in the company, valued at approximately $103,062,188.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 10,245 shares of company stock worth $268,052 over the last quarter. 21.50% of the stock is currently owned by company insiders.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).
Read More: Return on Investment (ROI)
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.